|
|
 |
|
Viewing report
|
|
|
|
Biogen Idec Inc.: SWOT Analysis & Company Profile
Business Review, June 2010, Pages: 26
Synopsis
Business Review’s Biogen Idec Inc. contains a company overview, key facts, locations and subsidiaries, news and events as well as a SWOT analysis of the company.
Summary
This SWOT Analysis company profile is a crucial resource for industry executives and anyone looking to quickly understand the key information concerning Biogen Idec Inc.’s business.
Business Review’s “Biogen Idec Inc. SWOT Analysis & Company Profile” reports utilize a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format.
Business Review strictly follows a standardized research methodology to ensure high levels of data quality and these characteristics guarantee a unique report.
Scope
- Examines and identifies key information and issues about (Biogen Idec Inc.) for business intelligence requirements
- Studies and presents Biogen Idec Inc.’s strengths, weaknesses, opportunities (growth potential) and threats (competition). Strategic and operational business information is objectively reported.
- The profile contains business operations, the company history, major products and services, prospects, key competitors, structure and key employees, locations and subsidiaries.
Reasons To Buy
- Quickly enhance your understanding of the company.
- Obtain details and analysis of the market and competitors as well as internal and external factors which could impact the industry.
- Increase business/sales activities by understanding your competitors’ businesses better.
- Recognize potential partnerships and suppliers.
- Obtain yearly profitability figures
Key Highlights
Biogen Idec Inc. (Biogen) is a leading biotechnology company, involved in development, manufacturing and commercialization of novel therapies used in the areas of oncology, neurology, immunology and cardiology. It offers products to address diseases such as multiple sclerosis, lymphoma, and rheumatoid arthritis. It has a broad pipeline of more than 20 products in phase II clinical trials. The company markets four products, namely, AVONEX, RITUXAN, TYSABRI and FUMADERM in more than 90 countries worldwide, principally in Canada, Australia, Japan and Europe. The company also provides informational, emotional, financial, and logistical support services to care givers and patients. Biogen operates 47 subsidiaries. Biogen is headquartered in Cambridge, Massachusetts, US.
|
|
|
|
